Roche has taken a significant step into metabolic dysfunction-associated steatohepatitis (MASH) treatment by agreeing to acquire 89bio for up to $3.5 billion. The deal centers on 89bio's phase III FGF21 analogue, pegozafermin, which aims to reduce liver fat, inflammation, and fibrosis, potentially reversing scarring in affected patients. This acquisition positions Roche competitively within the burgeoning MASH therapy market, highlighted by recent successes from Madrigal Pharmaceuticals and Novo Nordisk. The transaction includes a $14.50 per share payment and contingent milestones, emphasizing Roche's commitment to expanding its cardiometabolic portfolio.